Abstract
Eison, Arlene, S. and Michael S. Eison: Serotonergic Mechanisms in Anxiety. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1994, 18(1): 47–62. 1. 1. Anatomical, behavioral, neurochemical and electrophysiological evidence collectively support a role for central 5-HT in the modulation of anxiety and the anti-anxiety action of the benzodiazepines. 2. 2. The advent of selective agonists and antagonists for 5-HT receptor subtypes (5-HT 1, 5-HT 2, 5-HT 3) has rekindled investigation of the role of 5-HT in anxiety mechanisms. 3. 3. The azapirones represent a new class of agent which possesses affinity for 5-HT 1A receptors (partial agonists) and is active in anxiolytic animal models as well as in the clinic (buspirone) 4. 4. While preclinical data supporting the anxiolytic potential of 5-HT 2 antagonists remains controversial, a recent clinical study supports ritanserin's anxiolytic effects. 5. 5. Several animal models support the anxiolytic potential of the 5-HT 3 antagonist odansetron (GR38032F). Confirmation of it's therapeutic utility awaits clinical results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Progress in Neuro-Psychopharmacology and Biological Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
